Luciano Costa, MD, PhD, Shares Key Takeaways From the MASTER Trial in Multiple Myeloma
October 19th 2021CancerNetwork® sat down with Luciano Costa, MD, PhD, at the 2021 International Myeloma Workshop to discuss the benefit of treatment with daratumumab, carfilzomib, lenalidomide, and dexamethasone and the population of patients with newly diagnosed myeloma who will best benefit from treatment.
Luciano Costa, MD, PhD, Discusses Topline Data Utilizing KRd in Newly Diagnosed Myeloma
September 30th 2021CancerNetwork® sat down with Luciano Costa, MD, PhD, at the 2021 International Myeloma Workshop to talk about the most important data from the phase 2 MASTER trial in newly diagnosed multiple myeloma.
MRD Has Potential to Predict Outcomes for Patients With Myeloma Post-Stem Cell Transplantation
September 10th 2021Minimal residual disease negativity may predict outcomes for patients with multiple myeloma on maintenance therapy with lenalidomide who previously underwent autologous stem cell transplantation.
Larry Anderson, MD, PhD, Discusses CAR T-Cell Therapy For Multiple Myeloma at 2021 IMW
September 10th 2021CancerNetwork® sat down with Larry Anderson, MD, PhD, at the 18th International Myeloma Workshop to talk about how the emergence of CAR T-cell therapies in multiple myeloma affects multidisciplinary clinicians.
Treatment With KRd Plus Autologous Stem Cell Transplant Elicits Durable Survival Benefit in Myeloma
September 9th 2021Patients with multiple myeloma with standard or high-risk cytogenic abnormalities who were treated with carfilzomib, lenalidomide, and dexamethasone plus autologous stem cell transplant experienced promising responses.